M., & Pedersen, S
For those who experience persistent symptoms, working closely with healthcare providers can help determine if dose adjustments or additional management strategies might be beneficial
Both semaglutide and tirzepatide are GLP-1-based injectable weight loss medications, but tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates an additional hormonal pathway that amplifies metabolic effects
Telehealth companies typically offer an evaluation from a health care provider and a subscription to receive the medicine, if it's warranted
The concentration differs between productsOzempic delivers 0.25 mg, 0.5 mg, 1 mg, or 2 mg doses, while Wegovy provides 0.25 mg through 2.4 mg weekly doses in a titration schedule
The roles of these receptor populations are, however, unclear